文献速递眼底病与葡萄膜炎

女性激素治疗与非感染性葡萄膜炎风险:大型医疗索赔数据库研究

Risk of Noninfectious Uveitis with Female Hormonal Therapy in a Large Healthcare Claims Database.
PubMed 文献 · Ophthalmology · 2020-04-27

主要结局(两次诊断代码)下FHT与葡萄膜炎风险无显著关联(HR 0.99,95%CI 0.83-1.17,P=0.87);但替代结局(诊断加激素治疗记录)下风险轻度升高(HR 1.21,95%CI 1.04-1.41,P=0.01)。结论认为FHT总体对多数患者非感染性葡萄膜炎风险安全。

要点

  • 主要结局定义下FHT未显著增加非感染性葡萄膜炎风险(HR 0.99)。
  • 替代结局定义下FHT组葡萄膜炎风险轻度升高(HR 1.21)。
  • 前葡萄膜炎和≥45岁女性在替代结局下风险升高。

核心结论

  • 当葡萄膜炎定义结合诊断代码和激素治疗记录时,FHT暴露增加非感染性葡萄膜炎发生率,但风险轻度,多数患者可能安全。

研究设计与样本

  • 使用多变量Cox比例风险回归估计发病率,并通过倾向评分逆概率加权控制组间差异。

主要发现

  • 主要结局(新诊断代码后120天内再次出现非感染性葡萄膜炎代码)的HR为0.99(95%CI 0.83-1.17,P=0.87),无显著差异。
  • 替代结局(诊断代码后120天内激素处方或眼内激素注射代码)的HR为1.21(95%CI 1.04-1.41,P=0.01),FHT组风险更高。
  • 按解剖亚型,前葡萄膜炎在替代结局下暴露组风险更高(HR 1.23,95%CI 1.05-1.45,P=0.01),主要结局下无此现象。
  • 按年龄分层,≥45岁暴露女性在替代结局下风险更高(HR 1.23,95%CI 1.03-1.47,P=0.03);≤44岁女性HR相似(1.22)但未达统计学显著性(P=0.20)。

关键数值与推荐

  • 主要结局定义:新非感染性葡萄膜炎诊断代码后120天内再次出现非感染性葡萄膜炎代码。
  • 替代结局定义:葡萄膜炎诊断代码后120天内激素处方或眼内激素注射代码,替代第二次葡萄膜炎诊断代码。

临床怎么用

  • 对于多数使用FHT的女性,非感染性葡萄膜炎风险轻度,不应因此常规停止FHT。
  • 对≥45岁使用FHT的女性,若出现前葡萄膜炎表现,可考虑评估FHT相关风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine if female hormonal therapy (FHT) increases the incidence of noninfectious uveitis. DESIGN: Retrospective cohort study. PARTICIPANTS: Women exposed to FHT and matched women unexposed to FHT enrolled in a national insurance plan. METHODS: Estimation of noninfectious uveitis incidence used multivariable Cox proportional hazards regression. To account for differences between the exposed and unexposed cohorts, a propensity score for being prescribed FHT was created using logistic regression, and inverse probability of treatment weighting was performed. MAIN OUTCOME MEASURES: Incidence of noninfectious uveitis. For the primary outcome, incident noninfectious uveitis was defined as a new diagnosis code for noninfectious uveitis followed by a second instance of a noninfectious uveitis code within 120 days. For the alternative outcome definition, a corticosteroid prescription or code for an ocular corticosteroid injection within 120 days of the uveitis diagnosis code was used instead of the second uveitis diagnosis code. RESULTS: There were 217 653 women exposed to FHT and 928 408 women not unexposed to FHT. For the primary outcome, the hazard ratio (HR) for incident noninfectious uveitis was not significantly different between the FHT and unexposed cohorts (HR, 0.99; 95% confidence interval [CI], 0.83-1.17; P = 0.87). With the alternative outcome definition, the FHT cohort was more likely to develop uveitis (HR, 1.21; 95% CI, 1.04-1.41; P = 0.01). When examined by anatomic subtype, for anterior uveitis there was a greater likelihood of incident uveitis in the exposed cohort (HR, 1.23; 95% CI, 1.05-1.45; P = 0.01) for the alternative outcome definition but not for the primary outcome. With age stratification, women exposed to FHT aged ≥45 years at the time of FHT prescription were more likely to develop uveitis (HR, 1.23; 95% CI, 1.03-1.47; P = 0.03) for the alternative outcome definition. A similar HR (1.22) was seen for women aged ≤44 years at the time of prescription, but this association did not meet statistical significance (P = 0.20). CONCLUSIONS: Exposure to FHT increases the rate of incident noninfectious uveitis when uveitis is defined on the basis of both diagnostic codes and documentation of corticosteroid treatment. However, the risk is modest and FHT is likely safe with regard to noninfectious uveitis risk in the majority of patients exposed to these drugs.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Sobrin L, Yu Y, Susarla G, et al. Risk of Noninfectious Uveitis with Female Hormonal Therapy in a Large Healthcare Claims Database. Ophthalmology. 2020. PMID: 32353382. doi:10.1016/j.ophtha.2020.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。